

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q82144

Hiroshi OKAZAKI

Appln. No.: 10/564,819

Group Art Unit: 1649

Confirmation No.: 3159

Examiner: Not Yet Assigned

Filed: January 18, 2006

For: OLIGODENDROCYTE PRECURSOR CELLS AND METHOD OF OBTAINING AND CULTURING THE SAME

**SECOND REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT**

**ATTN:** Office of Initial Patent Examination

Filing Receipt Correction

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

We enclose a copy of the Corrected Official Filing Receipt for the above-identified application and request the following correction:

**FILING or 371(c)DATE**

[01/13/2006]

**01/18/2006**

Verification for the requested correction is indicated on the Applicant Transmittal Letter and date-stamped filing receipt filed January 18, 2006.


Respectfully submitted,

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

  
Susan J. Mack  
Registration No. 30,951

Date: September 16, 2008

SMG



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLAIMS	IND CLAIMS
10/564,819	01/13/2006	1649	4810	Q82144	60	9

CONFIRMATION NO. 3159

CORRECTED FILING RECEIPT

23373  
SUGHRUE MION, PLLC  
2100 PENNSYLVANIA AVENUE, N.W.  
SUITE 800  
WASHINGTON, DC 20037



OC000000031545536

Date Mailed: 08/13/2008

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

**Applicant(s)**

Hiroshi Okazaki, Potomac, MD;

**Assignment For Published Patent Application**

Otsuka Pharmaceutical Co., Ltd.

**Power of Attorney:** The patent practitioners associated with Customer Number 23373

**Domestic Priority data as claimed by applicant**

This application is a 371 of PCT/IB04/02670 \*  
which claims benefit of 60/487,933 07/18/2003

(\*)Data provided by applicant is not consistent with PTO records.

**Foreign Applications**

**If Required, Foreign Filing License Granted:** 04/21/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 10/564,819**

**Projected Publication Date:** Not Applicable

**Non-Publication Request:** No

**Early Publication Request:** No

**Title**

Oligodendrocyte Precursor Cells and Methods of Obtaining and Culturing the Same

**Preliminary Class**

435

**PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER**

**Title 35, United States Code, Section 184**

**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

January 18, 2006

**MAIL STOP PCT**

Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

PCT/IB2004/002670.  
-filed July 19, 2004

Re: Application of Hiroshi OKAZAKI  
OLIGODENDROCYTE PRECURSOR CELLS AND METHODS OF  
OBTAINING AND CULTURING THE SAME  
**Assignee: OTSUKA PHARMACEUTICAL CO., LTD.**  
Our Ref: Q82144

Dear Sir:

The following documents are submitted herewith in connection with the above application for the purpose of entering the National stage under 35 U.S.C. §371 and in accordance with the Patent Cooperation Treaty:

- ☒ a copy of the executed Declaration and Power of Attorney.
- ☒ a copy of the International Application.
- ☒ thirteen (13) sheets of drawings (Figs. 1-8C).
- ☒ a copy of Notification Concerning Submission or Transmittal of Priority Document.
- ☒ a copy of the executed Assignment and PTO 1595 form.
- ☒ an Information Disclosure Statement and a copy of the ISR.
- ☒ a PTO/SB/08 A & B (modified) listing the ISR references.
- ☒ a copy of each reference cited in the ISR.
- ☒ Preliminary Amendment.

In addition to the documents submitted herewith, it is assumed that copies of the International Application, the International Search Report and cited references, the International Preliminary Examination Report, and any Articles 19 and 34 amendments as required by §371(c) will be supplied directly by the International Bureau, but if further copies are needed, the undersigned will undertake to provide them upon request.

It is expressly requested that the national stage of processing be commenced immediately in accordance with 35 U.S.C. § 371(f).

National Stage of PCT/IB2004/002670

The Government filing fee is calculated as follows:

Total claims	<u>67</u>	-	<u>20</u>	=	<u>47</u>	x	\$50.00	=	\$2350.00
Independent claims	<u>9</u>	-	<u>3</u>	=	<u>6</u>	x	\$200.00	=	\$1200.00
Base Fee									\$300.00
Search Fee*									\$100.00
Examination Fee*									\$200.00
Multiple Dependent Claim Fee									\$360.00
<b>Total Filing Fee</b>									<u>\$4510.00</u>
<b>Recordation of Assignment</b>									<u>\$40.00</u>
<b><u>TOTAL FEE</u></b>									<u>\$4550.00</u>


\*The international search fee for all claims was paid to the USPTO, as the ISA.

Checks for the statutory filing fee of \$4510.00 and recordation of Assignment fee of \$40.00 are attached. The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this transmittal letter is attached.

Benefit is claimed from:

<u>Country</u>	<u>Application No</u>	<u>Filing Date</u>
U.S. Provisional	60/487,933	July 18, 2003

Respectfully submitted,



Drew Hissong  
Registration No. 44,765

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: January 18, 2006

1/D

SI-67

AP15KJJPCTA TO 18 JAN 2006

01-26-2006

Q82144

MODIFIED Form PTO-1595  
(Rev. 10/02)



SHEET

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

10/564819

103165404

Attached original documents or copy thereof.

To the Director of the U.S. F

1. Name of conveying party(ies):

Hiroshi OKAZAKI

2. Name and address of receiving party(ies):

OTSUKA PHARMACEUTICAL CO., LTD.  
2-9, Kanda Tsukasa-cho, Chiyoda-ku,  
Tokyo, Japan

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name  
☐ Other

Execution Date: January 17, 2006

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: January 17, 2006

A. Patent Application No.(s)  
Not Yet Assigned

B. Patent No.(s)  
Not Yet Assigned

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

SUGHRUE MION, PLLC

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

6. Total number of applications and patents involved:

1

7. Total fee (37 CFR 3.41): \$40.00

- ☒ Enclosed.  
☐ Authorized to be charged to Deposit Account No. 19-4880.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

8. Deposit Account Number:

19-4880

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Drew Hissong

Reg. No. 44,765

January 18, 2006

Date

Total number of pages including cover sheet, attachments, and documents: 2

Mail documents to be recorded with required cover sheet information to:

MAIL STOP ASSIGNMENT RECORDATION SERVICES

Director of the U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

01 20/2006 GREY1 00000111 10564819  
07 FC:8021 40.00 DP